The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Hasan Cagrı YıldırımYasin KutluEmel MutluMusa Barış AykanMustafa KorkmazSelim YalçınTeoman ŞakalarÖzde Melisa CelayirErkan KayıkçıoğluFerit AslanEmre HafızoğluYunus Emre AltıntaşMerve KeskinkılıçElvin ChalabiyevAbdussamet ÇelebiBengü DursunCaner KaparMiraç ÖzenÖmer AcarÖzgecan DülgarEngin KutSedat BiterFatih KusElvina AlmuradovaAtike Pınar ErdoğanSeray SarayDeniz Can GüvenEda Tanrıkulu ŞimşekNecdet ÜskentYasemin KemalBurcu ÇakarÖzgür AçıkgözSaadettin KılıçkapSercan AksoyPublished in: International journal of clinical oncology (2024)
This study demonstrates that palbociclib and ribociclib are effective and safe options for first-line treatment in male patients with HR + /HER2 - metastatic breast cancer. However, further prospective studies are warranted to establish their efficacy in this population.